News

 
Pall ForteBio Acquires the Pioneer SPR Product Line from SensiQ Technologies to Expand Its Label-Free Interaction Analysis Portfolio

2017-Jan-09

Freemont, CA, January 9, 2017 - Pall ForteBio acquires the Pioneer SPR Platform from SensiQ Technologies, expanding its portfolio of BLI-based biomolecular characterization instruments to include SPR-based small molecule fragment screening and more detailed biologics characterization.

   More...
Pall ForteBio Launches the Octet® K2 System, Increasing Access to Sensitive Binding Interactions Analysis

2015-Aug-04

PORT WASHINGTON, N.Y., August 4, 2015 — Pall ForteBio LLC, a leading supplier of instrumentation for accelerated drug discovery and development, today announced the launch of the Octet K2 system, a new entry point into the Octet line of label-free interaction analysis systems. Now available globally, the Octet K2 system offers high-performance, budget-friendly kinetic characterization of antibody, protein and small-molecule binding interactions.

   More...
ForteBio Launches Octet® HTX System for Accelerated Drug Development

2013-Sep-16

PORT WASHINGTON, N.Y., September 16, 2013 — ForteBio, a division of Pall Life Sciences and a leading supplier of instrumentation for accelerated drug discovery and development, today announced the launch of the Octet® HTX system, the new flagship member of the Octet line of label-free interaction analysis systems. The Octet HTX system addresses the acute industry need for increased analysis speed and sample throughput when characterizing large numbers of therapeutic candidates.

   More...
ForteBio Launches New Dip and Read™ Anti-FLAG Biosensor to Facilitate Protein Research and Drug Development

2013-Feb-12

PORT WASHINGTON, N.Y., February 12, 2013 — ForteBio, a division of Pall Life Sciences and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Dip and Read Anti-FLAG Biosensor for use on the company's Octet® and BLItz instrumentation systems. The new biosensor enables researchers to quickly and easily detect...    More...

ForteBio Launches Dip and Read Anti-Human Fab-CH1 Biosensor to Accelerate Human Biotherapeutic Drug Development

2013-Jan-09

PORT WASHINGTON, N.Y., January 09, 2013 — ForteBio, a division of Pall Life Sciences and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read Anti-Human Fab-CH1 biosensor. The new biosensor enables an easy and rapid method for quantitation and kinetic characterization of human Fab, F(ab')2 and IgG - critical processes in drug discovery. Dip and Read...    More...

ForteBio Launches Dip and Read™ Ni-NTA Biosensor for Protein Analysis

2012-May-31

PORT WASHINGTON, N.Y., May 31, 2012 — ForteBio®, a division of Pall Life Sciences (NYSE: PLL) and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the introduction of its Dip and Read™ Ni-NTA biosensor for use on its Octet® and BLItz™instrumentation platforms. The new biosensor is pre-immobilized with novel nickel-charged tri-nit...    More...

Pall Corp. Signs Agreement to Acquire Life Sciences Innovator ForteBio®

2011-Dec-19

PORT WASHINGTON, N.Y., December 19, 2011 — Pall Corporation (NYSE: PLL), a global leader in filtration, separation and purification, today announced it has entered into a definitive merger agreement to acquire ForteBio®, Inc., a leading provider of advanced analytical systems that accelerate the discovery and development of biotech drugs. The transaction is expected to close by February of 2012. Terms of the deal were not disclosed.

Headquartered ...    More...

ForteBio Introduces BLItz, a Revolutionary, Micro-Volume Label-Free Analysis Platform for Personal Assays

2011-Dec-05

San Diego, CA, December 5, 2011 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of BLItz™, a revolutionary new platform that will enable scientists — for the first time — to conduct label-free analyses of proteins using small sample volumes easily and cost-efficiently at their lab bench. The new platform was unveiled today at the IBC Antibody En...    More...

ForteBio Launches Dip and Read™ Anti-GST Biosensor

2011-Nov-29

MENLO PARK, CA, November 29, 2011 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the introduction of its Dip and Read™ Anti-GST biosensor for use on the company’s Octet® instrumentation platform. The new biosensor enables researchers to conduct quantitation and kinetic analyses with GST fusion proteins — widely u...    More...

ForteBio Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies

2011-Jun-08

MENLO PARK, CA, June 8, 2011 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Anti-Mouse IgG Fc Capture (AMC) biosensor for use on the company’s Octet® instrumentation platform. The new biosensor enables high-throughput rapid kinetic characterization and screening of mouse antibo...    More...

ForteBio Launches New Octet® RED96 System and Dip and Read™ Protein L Biosensor

2011-Feb-15

MENLO PARK, CA, February 15, 2011 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Octet RED96 System, as well as its new Dip and Read™ Protein L Biosensor for use on the company’s Octet platform. The product introductions further widen the scope and utility of the company’s flagship instrumentation system, whic...    More...

Hudson Robotics Chosen as Preferred Automation Vendor for ForteBio’s Label-Free Work Cell

2010-Oct-21

October 21, 2010, Springfield, NJ — Hudson Robotics, Inc., a leading provider of flexible solutions in laboratory automation, today announced they have been chosen as a preferred automation vendor for ForteBio's Label-Free Octet® platform work cell. This label-free work cell allows scientists to automate acquisition of protein-protein and protein-small molecule binding kinetic data, as well as direct quantitation assays - all of which can be car...    More...

ForteBio Announces Launch of Protein G Biosensor for Use on Company's Octet® Instruments

2010-Sep-03

MENLO PARK, CA, September 3, 2010 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG, an antibody molecule), from solution. Because it runs on the company’s label-free Octet instrumentation pl...    More...

ForteBio Launches New-Generation Octet® QKe Instrument

2010-Apr-20

MENLO PARK, CA, April 20, 2010 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Octet QKe instrumentation system. The new system, the next generation of the company’s initial eight-channel Octet QK instrument, provides significantly increased sensitivity, enabling analysis of small proteins and peptides. Addi...    More...

Tecan and ForteBio Automate Label-Free assays for Bioprocess and Drug Discovery Applications

2010-Mar-09

March 9, 2010 — Tecan has become ForteBio’s preferred automation partner for real-time, label-free assays to support bioprocess and drug discovery workflows. The two companies have worked together to integrate the new ForteBio Octet® 384 platform, consisting of the Octet RED384 and the Octet QK384, on Tecan’s Freedom EVO® liquid handling workstation. The result is a robust, off-the-shelf integration that offers increas...    More...

ForteBio Launches New Dip and Read™ Residual Protein A Detection Kit; Introduces Sidekick™ Offline Biosensor Immobilization Station for all Octet® Instruments

2010-Jan-11

MENLO PARK, CA, January 11, 2010 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Dip and Read Residual Protein A Detection Kit for use on the company’s Octet platform. The new assay enables drug developers to accurately identify and measure levels of Protein A with unprecedented speed and minimal hands-on time. Th...    More...

ForteBio Launches Dip and Read™ Immunogenicity Assay Kit for Rapid Detection of Anti-Drug Antibodies

2009-Sep-16

MENLO PARK, CA, September 16, 2009 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, announced today that it has launched the new Dip and Read Immunogenicity Assay Kit for rapid detection of anti-drug antibodies (ADA) for use on the company's Octet® platform. The new assay kit provides life science researchers with new levels of throughput, speed and flex...    More...

ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet® RED384 and The Octet QK384

2009-Jun-22

MENLO PARK, CA, June 22, 2009 — ForteBio, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, announced today that it has launched two next-generation instruments: the Octet RED384 for protein, peptide, small molecule and fragment screening; and the Octet QK384 for protein and antibody assays. The new instruments will début this week at the 2009 American Association of Pharmaceutic...    More...

ForteBio Launches New Assay Capabilities for High-Sensitivity Protein Quantitation and Fragment Screening on its Octet® Platform

2009-May-27

MENLO PARK, CA, May 27, 2009 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced that it has launched two new assay modules — for high-sensitivity protein quantitation and fragment screening, respectively — for use on the company's Octet® instrumentation platform. The new modules are available via software upgrades and...    More...

ForteBio Launches New Biosensor for Kinetic Analysis and Screening of Human IgG Antibodies

2009-Mar-03

MENLO PARK, CA, March 3, 2009 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Anti-Human IgG Fc Capture (AHC) biosensor for use on the company’s Octet® instrumentation platform. The new biosensor enables more cost-effective, easy-to-use and rapid kinetic characterization and screening of human lgG antib...    More...

ForteBio, Inc. Closes $25 Million in Series C Financing

2008-Sep-23

MENLO PARK, CA, September 23, 2008 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of life science and pharmaceutic products, today announced the closing of $25 million in Series C financing, led by OrbiMed Advisors, a top global healthcare investment firm. MPM Capital also participated as a new investor in this financing round, as did existing investors Alloy Ventures, Versant Ventures, The Vertical Group a...    More...

ForteBio Announces New Octet RED System for Drug Candidate Characterization and Selection

2008-Apr-03

MENLO PARK, CA, April 3, 2008 — ForteBio®, Inc., a life science company that develops and sells analytical tools to accelerate the development of therapeutic products, today announced the launch of the Octet® RED System, for label-free, real-time kinetic analysis of drug compounds. The new system brings unparalleled ease-of-use, sensitivity, throughput and affordability to the analysis of small molecules, peptides and proteins for rese...    More...

ForteBio Announces Executive Change

2007-Sep-18

MENLO PARK, Calif. — September 18, 2007 — ForteBio, Inc., a rapidly growing life science company that develops and commercializes analytical instruments and consumables to accelerate and improve therapeutics development, announced today that Joseph D. Keegan, Ph. D., has been named president and chief executive officer, beginning September 24, 2007. ForteBio founding CEO Winnie H. Wan, Ph.D., who is credited with building the company into an emerging leader in the...    More...

ForteBio Expands International Distribution Network

2007-Aug-20

MENLO PARK, Calif. — August 20, 2007 — ForteBio, Inc., a leading developer of label-free, real-time systems for biomolecular interaction analysis, announced today that it has signed two new distributors to sell and distribute its Octet System of instruments and related consumables. The company named Bucher Biotec AG, Switzerland, as its exclusive Swiss distributor and Millennium Science Pty Ltd, Australia, as its distribution partner in Australia and New Zealand....    More...

ForteBio Strengthens Portfolio with New Biosensors for Research and Development

2007-Aug-13

MENLO PARK, Calif. — August 13, 2007 — ForteBio, Inc., a leading developer of label-free, real-time systems for biomolecular interaction analysis, today announced two new product extensions to its Octet™ System. The Anti-Murine IgG Biosensor — Quantitation grade, and the Streptavidin High Binding FA Biosensor — Screening grade, extend the Octet System's concentration determination and kinetic analysis capabilities, respectively, broadening t...    More...

New Biosensors expand applications for research and assay development

2007-Jun-29

In ForteBios' continuing effort to expand the applications on the Octet System, we are launching two new biosensors for the kinetic analysis and concentration determination for research, development and production of antibody and protein therapeutics.

The following Screening and Quantitation grade biosensors are now available for use on the Octet System.

Anti-Murine IgG Biosensors - Quantitation Grade

• Determine mouse or rat IgG concentration based on a standard ca...    More...

ForteBio Launches New Biosensors to Increase the Flexibility of the Octet System

2006-Dec-07

MENLO PARK, Calif. — December 7, 2006 — ForteBio, Inc. announced today the launch of the Amine Reactive and Protein A Biosensors for use on ForteBio's Octet System, a label-free, real-time detection system for the analysis of molecular interactions. The new biosensors expand the menu of Octet applications, providing convenient kinetic analysis and concentration determination for the development of antibody and protein therapeutics.

The ForteBio Octet ...    More...

ForteBio Adds Bernelle Saperstein to its Management Team

2006-Jul-18

MENLO PARK, Calif. — July 18, 2006 — ForteBio, Inc., developer of label-free systems for real-time detection and analysis of molecular interactions, said today that Bernelle H. Saperstein has joined the company as Vice President, Manufacturing Operations, a new position. Ms. Saperstein comes to ForteBio from BD-Immunocytometry Systems, where she led a large team responsible for manufacturing and testing reagents for cell analysis.

“Bernelle is an ext...    More...

ForteBio Introduces the Octet System
for Antibody and Protein Therapeutics Development

2005-Nov-29

MENLO PARK, Calif. — November 29, 2005— ForteBio, Inc. today announced the commercial introduction of the company's first product, the Octet™ System for label-free, real-time detection and analysis of molecular interactions. The next generation of analytical tools for life science research, Octet accelerates antibody development by generating real-time quantitative and kinetics results quickly and easily. Ready to use, consumable biosensors provide a co...    More...

ForteBio Raises 17.3 Million in Series B Financing - Funding Will Support Launch

2005-Oct-26

MENLO PARK, Calif. — October 26, 2005 — ForteBio, Inc., a life sciences company providing tools for the detection and analysis of biomolecules and their interactions, today announced the close of a $17.3 million Series B Preferred Stock financing. The round was led by The Vertical Group, a New Jersey-based venture capital firm that is focused on the fields of medical technology and biotechnology. All of the company's existing investors, Agilent Ventures, Allo...    More...